57676-54-7

Basic information

• Product Name: 2-(4-methylphenyl)acetohydrazide
• Synonyms: 2-(4-methylphenyl)acetohydrazide;Albb-007085;2-(4-methylphenyl)ethanehydrazide;p-Tolyl-aceticacidhydrazide
• CAS NO: 57676-54-7
• Molecular Formula: C₉H₁₂N₂O
• Molecular Weight: 164.21
• Mol File: 57676-54-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 374.4°C at 760 mmHg
• Flash Point: 180.2°C
• Appearance: /
• Density: 1.108g/cm³
• Vapor Pressure: 8.38E-06mmHg at 25°C
• Refractive Index: 1.558
• CAS DataBase Reference: 2-(4-methylphenyl)acetohydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-methylphenyl)acetohydrazide(57676-54-7)
• EPA Substance Registry System: 2-(4-methylphenyl)acetohydrazide(57676-54-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 57676-54-7(Hazardous Substances Data)

Usage

General Description

2-(4-methylphenyl)acetohydrazide is a chemical compound with the molecular formula C10H14N2O. This organic compound belongs to the class of phenylacetohydrazides. It is composed of a phenyl group (containing a methyl substituent at the para position) attached to an acetyl group through a hydrazide linkage. It appears as a solid and its properties such as solubility, melting point, and boiling point, may vary based on conditions like temperature and pressure. Usage, safety implications, and methods of synthesis for 2-(4-methylphenyl)acetohydrazide can be found in various scientific research and industry-specific material.

InChI:InChI=1/C9H12N2O/c1-7-2-4-8(5-3-7)6-9(12)11-10/h2-5H,6,10H2,1H3,(H,11,12)

Upstream product

• 23786-13-2 methyl p-tolylacetate 
• 2947-61-7 (4-methylphenyl)acetonitrile 
• 622-47-9 4-tolylacetic acid 

Downstream Products

• 34546-97-9 5-(4-methyl-benzyl)-3H-[1,3,4]oxadiazol-2-one 
• 57706-27-1 5,5'-bis-(4-methyl-benzyl)-2,3,2',3'-tetrahydro-3,3'-(2-oxa-propane-1,3-diyl)-bis-[1,3,4]oxadiazole 
• 126381-20-2 4-(4-Methoxy-phenyl)-5-(4-methyl-benzyl)-2,4-dihydro-[1,2,4]triazol-3-one 
• 126381-21-3 4-(4-Isopropoxy-phenyl)-5-(4-methyl-benzyl)-2,4-dihydro-[1,2,4]triazol-3-one 
• 126381-22-4 5-(4-Methyl-benzyl)-4-(4-propoxy-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one 
• 945732-95-6 [(R)-1-[4-Ethyl-5(4-methylbenzyl)-4H-[1,2,4]triazol-3-yl]-ethyl]-carbamic acid t-butyl ester 
• 875899-03-9 tert-butyl [(1S,3S)-3-({2-[(4-methylphenyl)acetyl]hydrazino}carbonyl)cyclopentyl]carbamate 
• 502685-85-0 C₁₀H₁₂N₄ 
• 1456614-17-7 C₁₄H₁₇N₅O₂S 
• 1456613-95-8 2-(4-methylbenzyl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one 

Relevant articles and documents

Synthesis, in-vitro, in-vivo anti-inflammatory activities and molecular docking studies of acyl and salicylic acid hydrazide derivatives

Over the course of time several drugs have been synthesized and are available in market for the treatment of inflammation. However, they were unable to cure effectively and associated with side effects. To effectively deal with such diseases, heterocycles and their derivatives have gained their special position. For this reason 1,3,4-oxadiazole (15–16), 1,2,4-triazole (17–18), Schiff base (19–24) and 3,5-disubstituted pyrazole (25) derivatives were synthesized starting from salicylic acid and acyl acid hydrazides (12–14) as COX-1 and COX-2 inhibitors. In vivo anti-inflammatory activities were also tested by carrageenan-induced mice paw edema against albino mice of any sex. Structures of all the synthesized compounds were confirmed by FT-IR and 1H NMR analysis. Schiff base derivative of 4-amiontirazole (24) with IC50 value of 1.76 ± 0.05 (COX-2) and 117.8 ± 2.59 emerged as potent COX-2 inhibitor. Furthermore, we also performed in-vivo anti-inflammatory investigations by using carrageenan induced paw edema test. From in-vivo anti-inflammatory activities, it was found that after 1 h the maximum percentage inhibition 15.8% was observed by compound 14 which is comparable with that of the standard drug followed by the compound 18 with percentage inhibition of 10.5%. After 3 h, the maximum percentage inhibition was observed by compound 18 with 22.2% and compound 14 with 16.7%. After 5 h the maximum percentage inhibition was observed by compound 18 with 29.4% followed by compound 16 with 23.5%. We further explore the mechanism of the inhibition by using docking simulations. Docking studies revealed that the selective COX-2 inhibitors established interactions with additional COX-2 enzyme pocket residues.

Zur Synthese von 3-Arylmethyl-4-(p-alkoxyphenyl)-1,2,4-triazolin-5-onen

-